None
EN
Xenon Pharmaceuticals Q2 Earnings Call Highlights
['Tyrone Williams']
Daily Political
Consumables Growth Offset by Instrument DeclinesTotal consumables revenue increased 7% year over year, with growth in both single-cell and spatial products.
Single-cell consumables revenue rose 3%, supported by double-digit growth in reaction volumes, while spatial consumables revenue increased 16%.
Chief Financial Officer Adam Taich said Xenium was the main driver of spatial consumables growth, though both Xenium and Visium consumables posted sequential growth.
Chromium instrument revenue fell 46%, while spatial instrument revenue declined 48%, primarily because of fewer systems sold.
Excluding non-recurring license and royalty revenue, revenue in the Americas rose 6% and revenue in Europe, the Middle East and Africa increased 15%.